Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 37.74% is in line with its 5-year average of 37.60%, around the middle of its 5-year range (32.95%–43.70%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.27% above its 12-month average of 36.54%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
37.74%
GROSS MARGIN AVG TTM
36.54%
GROSS MARGIN AVG 3Y
36.15%
GROSS MARGIN AVG 5Y
37.60%
GROSS MARGIN AVG 10Y
35.59%
GROSS MARGIN AVG 15Y
34.15%
GROSS MARGIN AVG 20Y
32.66%
CURRENT VS TTM AVG
+3.27%
CURRENT VS 3Y AVG
+4.38%
CURRENT VS 5Y AVG
+0.36%
CURRENT VS 10Y AVG
+6.04%
CURRENT VS 15Y AVG
+10.52%
CURRENT VS 20Y AVG
+15.54%
SECTOR MEDIAN · HEALTHCARE
58.99%
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-36.03%
vs the sector median at left
West Pharmaceutical Services, Inc.
Market Cap
$24.73B
Gross Margin
37.74%
TTM Avg
36.54%
3Y Avg
36.15%
5Y Avg
37.60%
Market Cap
$24.54B
Gross Margin
92.62%
TTM Avg
92.70%
3Y Avg
93.10%
5Y Avg
93.74%
Market Cap
$26.21B
Gross Margin
33.15%
TTM Avg
32.39%
3Y Avg
33.17%
5Y Avg
35.04%
Market Cap
$26.44B
Gross Margin
27.85%
TTM Avg
27.30%
3Y Avg
28.39%
5Y Avg
31.16%
Market Cap
$21.88B
Gross Margin
86.14%
TTM Avg
88.58%
3Y Avg
89.63%
5Y Avg
90.66%
Market Cap
$29.04B
Gross Margin
59.30%
TTM Avg
57.84%
3Y Avg
57.54%
5Y Avg
57.23%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.73B | 37.74% | 36.54% | 36.15% | 37.60% |
| Incyte Corporation (INCY)vs › | $24.54B | 92.62% | 92.70% | 93.10% | 93.74% |
| Moderna, Inc. (MRNA)vs › | $24.03B | 55.35% | 54.80% | 53.09% | 65.45% |
| BioNTech SE (BNTX)vs › | $23.31B | 73.26% | 78.98% | 81.24% | 82.89% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.21B | 33.15% | 32.39% | 33.17% | 35.04% |
| STERIS plc (STE)vs › | $23.22B | 43.97% | 44.13% | 43.77% | 43.82% |
| Labcorp Holdings Inc. (LH)vs › | $26.44B | 27.85% | 27.30% | 28.39% | 31.16% |
| United Therapeutics Corporation (UTHR)vs › | $21.88B | 86.14% | 88.58% | 89.63% | 90.66% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.04B | 59.30% | 57.84% | 57.54% | 57.23% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.60B | 79.72% | 83.69% | 83.53% | 83.62% |
Gross Margin
37.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 37.74% |
| 2026-03-31 | 35.08% |
| 2025-12-31 | 37.75% |
| 2025-09-30 | 36.49% |
| 2025-06-30 | 35.66% |
| 2025-03-31 | 33.33% |
| 2024-12-31 | 36.66% |
| 2024-09-30 | 35.51% |
| 2024-06-30 | 32.95% |
| 2024-03-31 | 33.27% |
| 2023-12-31 | 38.11% |
| 2023-09-30 | 38.73% |
| 2023-06-30 | 38.74% |
| 2023-03-31 | 37.80% |
| 2022-12-31 | 37.18% |
| 2022-09-30 | 38.97% |
| 2022-06-30 | 41.45% |
| 2022-03-31 | 39.57% |
| 2021-12-31 | 40.14% |
| 2021-09-30 | 40.83% |
| 2021-06-30 | 43.70% |
| 2021-03-31 | 40.64% |
| 2020-12-31 | 36.45% |
| 2020-09-30 | 34.82% |
| 2020-06-30 | 36.91% |
| 2020-03-31 | 33.99% |
| 2019-12-31 | 33.17% |
| 2019-09-30 | 32.32% |
| 2019-06-30 | 33.55% |
| 2019-03-31 | 33.05% |
| 2018-12-31 | 31.47% |
| 2018-09-30 | 31.39% |
| 2018-06-30 | 31.84% |
| 2018-03-31 | 32.51% |
| 2017-12-31 | 31.11% |
| 2017-09-30 | 31.56% |
| 2017-06-30 | 31.50% |
| 2017-03-31 | 34.61% |
| 2016-12-31 | 32.21% |
| 2016-09-30 | 32.15% |
| 2016-06-30 | 34.36% |
| 2016-03-31 | 34.05% |
| 2015-12-31 | 33.25% |
| 2015-09-30 | 31.44% |
| 2015-06-30 | 32.86% |
| 2015-03-31 | 32.66% |
| 2014-12-31 | 31.36% |
| 2014-09-30 | 30.88% |
| 2014-06-30 | 33.02% |
| 2014-03-31 | 30.68% |
| 2013-12-31 | 31.11% |
| 2013-09-30 | 30.87% |
| 2013-06-30 | 32.19% |
| 2013-03-31 | 32.91% |
| 2012-12-31 | 30.33% |
| 2012-09-30 | 29.76% |
| 2012-06-30 | 30.39% |
| 2012-03-31 | 31.96% |
| 2011-12-31 | 28.88% |
| 2011-09-30 | 27.72% |
| 2011-06-30 | 27.48% |
| 2011-03-31 | 29.79% |
| 2010-12-31 | 28.18% |
| 2010-09-30 | 27.52% |
| 2010-06-30 | 29.52% |
| 2010-03-31 | 29.92% |
| 2009-12-31 | 28.60% |
| 2009-09-30 | 27.69% |
| 2009-06-30 | 30.15% |
| 2009-03-31 | 28.59% |
| 2008-12-31 | 28.43% |
| 2008-09-30 | 25.76% |
| 2008-08-05 | 29.93% |
| 2008-03-31 | 30.85% |
| 2007-12-31 | 27.53% |
| 2007-09-30 | 26.49% |
| 2007-06-30 | 29.09% |
| 2007-03-31 | 31.21% |
| 2006-12-31 | 28.29% |
| 2006-09-30 | 26.92% |
| 2006-06-30 | 29.35% |
| 2006-03-31 | 30.03% |
| 2005-12-31 | 26.47% |
| 2005-09-30 | 24.12% |
| 2005-06-30 | 29.25% |
| 2005-03-31 | 31.04% |
| 2004-12-31 | 26.60% |
| 2004-09-30 | 27.12% |
| 2004-06-30 | 30.99% |
| 2004-03-31 | 30.39% |
| 2003-12-31 | 33.39% |
| 2003-09-30 | 29.81% |
| 2003-06-30 | 32.75% |
| 2003-03-31 | 30.90% |
| 2002-12-31 | 27.56% |
| 2002-09-30 | 25.45% |
